Dementia and Neurodegeneration — Imaging Patterns

Neurodegenerative disease leaves predictable imaging fingerprints — atrophy patterns on T1 MPRAGE (which lobe, which nucleus), signal abnormalities on T2 / SWI / DWI for specific diagnoses, and molecular biomarkers on PET (amyloid, tau, FDG, DaTscan). This page maps the patterns to the syndromes — AD, FTD, DLB, MSA, PSP, CBD, CJD, NPH — and the signs you should never miss.

🔹 Bottom Line: Dementia & Neurodegen MRI

  • Alzheimer disease (AD): bilateral medial temporal + parietal atrophy; FDG parietotemporal hypometabolism + posterior cingulate; amyloid PET positive; tau PET positive in MTL → cortex.
  • DLB: relatively preserved hippocampi; DAT-SPECT abnormal; FDG occipital hypometabolism + cingulate island sign; MIBG reduced.
  • FTD (bvFTD): frontal + anterior temporal atrophy; FDG frontal hypometabolism; amyloid PET typically negative.
  • PSP: midbrain atrophy (“hummingbird,” “morning glory” signs); MR Parkinsonism Index; FDG midbrain + frontal hypometabolism.
  • MSA: cerebellar / brainstem atrophy (MSA-C: “hot cross bun” pons; MSA-P: putaminal atrophy + slit-like dorsolateral T2 hyperintensity).
  • CBD: asymmetric frontoparietal atrophy contralateral to clinical signs.
  • CJD: cortical ribbon DWI restriction + basal ganglia + pulvinar (variant) or pulvinar/cortical (sporadic).
  • NPH: ventriculomegaly out of proportion to atrophy + DESH pattern + Evans index >0.3 + callosal angle <90°.
  • CAA: lobar microbleeds + cortical superficial siderosis (Boston 2.0 criteria).

Alzheimer Disease (AD)

Structural MRI

  • Medial temporal lobe atrophy: hippocampus + entorhinal cortex (Scheltens MTA score 0–4).
  • Parietal atrophy: precuneus + posterior cingulate (Koedam visual score).
  • Bilateral, symmetric, progressive.
  • Spares sensorimotor cortex.
  • Whole-brain atrophy + ventricular enlargement (Evans index rises).

Functional / Molecular Imaging

  • FDG-PET: bilateral parietotemporal + posterior cingulate / precuneus hypometabolism. Spares sensorimotor + occipital.
  • Amyloid PET: positive (loss of gray-white contrast).
  • Tau PET: positive starting MTL (Braak I-II) → temporoparietal (III-IV) → diffuse cortical (V-VI).

AD Variants

  • Logopenic PPA: left temporoparietal atrophy + amyloid-positive in most.
  • Posterior cortical atrophy (PCA): bilateral parieto-occipital atrophy; often AD pathology.
  • Frontal variant AD: mimics FTD; amyloid PET positive distinguishes.

Frontotemporal Dementia (FTD) Spectrum

Behavioral Variant FTD (bvFTD)

  • Frontal + anterior temporal atrophy — bilateral but often asymmetric.
  • Sparing of posterior cortex (early).
  • FDG-PET: bilateral frontal hypometabolism.
  • Amyloid PET: typically negative.

Semantic Variant PPA (svPPA / Semantic Dementia)

  • Anterior temporal lobe atrophy — typically asymmetric (often left).
  • “Knife-edge” temporal pole.
  • FDG: anterior temporal hypometabolism.

Non-Fluent Variant PPA (nfvPPA)

  • Left inferior frontal + insular atrophy.
  • FDG: left inferior frontal hypometabolism.

FTD-MND (Motor Neuron Disease)

  • FTD + ALS-like motor signs.
  • C9orf72 hexanucleotide expansion in many cases.

Dementia with Lewy Bodies (DLB)

Structural MRI

  • Relatively preserved hippocampi compared to AD.
  • Generalized atrophy possible.
  • No specific structural sign.

Molecular / Functional Imaging

  • DAT-SPECT (DaTscan): abnormal — asymmetric putaminal uptake loss.
  • I-123 MIBG cardiac scintigraphy: reduced cardiac uptake (sympathetic denervation).
  • FDG-PET: occipital hypometabolism + “cingulate island sign” (preserved posterior cingulate relative to surrounding parietal hypometabolism) — distinguishes from AD.
  • Polysomnography: RBD (REM sleep behavior disorder) is a core feature.

Progressive Supranuclear Palsy (PSP)

Structural MRI Signs

  • Hummingbird sign: midbrain atrophy with preserved pons → midbrain looks like a hummingbird beak on sagittal T1.
  • Morning glory sign: concave (atrophic) midbrain tegmentum on axial.
  • Mickey Mouse sign: atrophic midbrain with prominent cerebral peduncles.
  • MR Parkinsonism Index (MRPI): (P/M × MCP/SCP) — high values support PSP.
  • Midbrain : pons ratio <0.52 supports PSP.
  • Cerebral peduncle and superior cerebellar peduncle atrophy.

Functional Imaging

  • FDG-PET: bilateral midbrain + frontal hypometabolism.
  • DAT-SPECT: abnormal (but doesn’t distinguish from PD).

Multiple System Atrophy (MSA)

MSA-C (Cerebellar Predominant)

  • Cerebellar atrophy.
  • Middle cerebellar peduncle atrophy.
  • Pontine atrophy + “hot cross bun” sign: cruciform T2 hyperintensity in pons (degenerated pontocerebellar fibers).

MSA-P (Parkinsonian Predominant)

  • Putaminal atrophy + low T2 signal (iron).
  • Slit-like dorsolateral putaminal T2 hyperintensity.
  • “Putaminal rim sign” (T2 hyperintense rim on 1.5T; less specific on 3T due to normal rim).

Common to Both

  • Autonomic dysfunction.
  • DAT-SPECT abnormal.
  • MIBG: variable.

Corticobasal Degeneration (CBD)

Imaging

  • Asymmetric frontoparietal atrophy contralateral to the clinically affected side.
  • FDG-PET: asymmetric frontoparietal + basal ganglia hypometabolism.
  • DAT-SPECT: abnormal (often asymmetric).

Huntington Disease (HD)

Imaging

  • Caudate + putaminal atrophy: caudate “flattening” of normally convex curve into lateral ventricle → “boxcar” ventricles.
  • Frontal atrophy.
  • FDG-PET: caudate + putaminal hypometabolism (early, before structural atrophy).

Creutzfeldt-Jakob Disease (CJD)

Sporadic CJD (sCJD)

  • Cortical ribbon DWI restriction: highly suggestive of sCJD in the appropriate rapidly progressive dementia context — but NOT pathognomonic. Mimics include status epilepticus / postictal change, severe hypoglycemia, hypoxic-ischemic injury, HSV encephalitis, hyperammonemia, and MELAS stroke-like episodes. Always correlate with EEG, CSF (14-3-3, RT-QuIC), and clinical trajectory.
  • Basal ganglia (caudate + putamen) DWI restriction.
  • FLAIR hyperintensity in same regions.
  • Asymmetric findings common.
  • Spares thalamus typically.

Variant CJD (vCJD)

  • Pulvinar sign: bilateral posterior thalamus (pulvinar) FLAIR/T2 hyperintensity — highly characteristic.
  • “Hockey stick sign”: pulvinar + dorsomedial thalamus.
  • Cortical involvement less prominent than sporadic.

Genetic CJD

  • Variable imaging features.
  • PRNP sequencing confirms (see Genetics).

Normal Pressure Hydrocephalus (NPH)

Imaging Criteria

  • Ventriculomegaly out of proportion to atrophy: Evans index >0.3 (frontal horn width / max biparietal diameter).
  • DESH pattern (Disproportionately Enlarged Subarachnoid space Hydrocephalus): tight high convexity sulci + enlarged Sylvian fissures + enlarged ventricles.
  • Callosal angle <90° on coronal at the level of posterior commissure.
  • Transependymal CSF flow: smooth periventricular T2/FLAIR halo.
  • Aqueduct CSF flow void: prominent on T2 (high-velocity flow).

Imaging Mimics

  • Age-related ventriculomegaly (proportional to atrophy) — NOT NPH.
  • Other communicating hydrocephalus (post-SAH, post-meningitis).

Cerebral Amyloid Angiopathy (CAA)

Imaging

  • Lobar microbleeds (SWI): cortical/subcortical, multiple, elderly, sparing deep gray.
  • Cortical superficial siderosis: linear hemosiderin deposition along cortex (SWI).
  • Lobar ICH: posterior > anterior; classic location for CAA.
  • White matter changes: leukoaraiosis (especially posterior).
  • Boston 2.0 criteria for CAA diagnosis (multidimensional imaging-based).
  • Distinguishes from hypertensive vasculopathy (deep microbleeds).

Small Vessel Disease (SVD) / Subcortical Vascular Dementia

Imaging Features

  • White matter hyperintensities (WMH): confluent periventricular T2/FLAIR.
  • Lacunes: small (<15 mm) deep infarcts in lenticulostriate / pontine / thalamoperforator territory.
  • Microbleeds: deep (basal ganglia, thalamus, pons) on SWI.
  • Perivascular spaces dilated: especially in basal ganglia (état criblé).
  • Fazekas score for WMH severity (0–3 periventricular + 0–3 deep).

CADASIL

  • Anterior temporal pole T2 hyperintensity: characteristic.
  • External capsule + corpus callosum (genu) T2 hyperintensities.
  • Deep gray microbleeds + lacunes.
  • NOTCH3 mutation (see Genetics).

Adult Leukodystrophies (Briefly)

  • ALSP (CSF1R): frontal-predominant white matter + thin corpus callosum + adult onset.
  • X-ALD (adrenomyeloneuropathy): adult-onset spastic paraparesis + neuropathy + adrenal insufficiency; MRI may be normal in AMN; cerebral form shows posterior white matter T2 hyperintensity + enhancement.
  • CTX: cerebellar + cerebral white matter + dentate signal change.
  • See Leukodystrophy / Genetics pages for full coverage.

🔹 Clinical Relevance: Imaging in the Dementia Workup

  • Reversible causes first: NPH (DESH + callosal angle), B12 / thyroid (lab), tumor (post-contrast MRI), SDH (CT/MRI), CAA-related inflammation (steroid-responsive).
  • AD diagnosis: MTL atrophy on MRI + confirmed amyloid pathology (amyloid PET or CSF biomarkers) + supportive tau evidence (tau PET, CSF p-tau181). Tau PET supports but doesn’t establish AD alone — interpret in the broader biomarker context.
  • Lecanemab / donanemab eligibility: requires confirmation of amyloid pathology before treatment, by amyloid PET OR CSF biomarkers (Aβ42/40 ratio, p-tau181). Validated plasma assays emerging in triage workflows.
  • AD vs FTD: pattern of atrophy + FDG-PET (parieto-temp vs frontal) + amyloid PET (positive vs negative).
  • AD vs DLB: DAT-SPECT (abnormal in DLB) + cingulate island sign on FDG + RBD + parkinsonism + visual hallucinations.
  • PSP vs PD: hummingbird sign + early postural instability + vertical gaze palsy.
  • MSA-C vs SCA: hot cross bun + putaminal atrophy + autonomic dysfunction → MSA.
  • Rapidly progressive dementia: think CJD (DWI ribbon), autoimmune encephalitis, paraneoplastic, infectious — escalate to LP + CSF biomarkers + MRI + targeted antibody panels.
  • Lobar microbleeds + cortical superficial siderosis: CAA — anticoagulation risk discussion.

Pitfalls and Pearls

  • Hippocampal atrophy is not specific to AD: also FTD, vascular dementia, CJD, normal aging.
  • Cingulate island sign on FDG-PET: highly specific for DLB.
  • Hummingbird sign + axial morning glory: PSP.
  • Hot cross bun pons: MSA-C.
  • Slit-like dorsolateral putaminal T2 hyperintensity: MSA-P (more reliable than putaminal rim on 3T).
  • Cortical ribbon DWI restriction: highly suggestive of sCJD in a rapidly progressive dementia context — not pathognomonic. Mimics: status / postictal, hypoglycemia, HIE, HSV encephalitis, hyperammonemia, MELAS. Correlate with EEG + 14-3-3 + RT-QuIC.
  • Bilateral pulvinar T2 hyperintensity: variant CJD; also Fabry, mitochondrial.
  • Hockey stick sign: variant CJD pulvinar + dorsomedial thalamus.
  • NPH vs atrophy: DESH pattern + callosal angle <90° supports NPH; proportional sulcal + ventricular enlargement = atrophy.
  • Amyloid PET positivity rises with age: ~30% of cognitively normal 70-year-olds positive; clinical context essential.
  • Tau PET correlates with cognitive decline better than amyloid does — tau is the “executor.”
  • Boston 2.0 criteria for CAA: incorporate lobar microbleeds + cortical superficial siderosis + lobar ICH + age.
  • CAA-related inflammation (CAA-ri): subacute encephalopathy + leukoencephalopathy + microbleeds + responds to steroids — don’t miss it.
  • “Knife-edge” temporal pole: semantic dementia.
  • Boxcar ventricles + caudate flattening: HD.
  • Anti-IgLON5 disease: hypothalamic + brainstem MRI changes + REM sleep behavior disorder + dysphagia — emerging autoimmune/tauopathy syndrome.

References

  1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
  2. Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017;32(6):853-864.
  3. Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022;37(6):1131-1148.
  4. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(10):2659-2668.
  5. Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714-725.
  6. Relkin N, Marmarou A, Klinge P, et al. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57(3 Suppl):S4-S16.
  7. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535-562.